Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Two Subcutaneous Dosing Regimens of ATL1103 in Acromegaly
2012-003147-30Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Nov 2012
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of atesidorsen in acromegaly, sponsored by Percheron Therapeutics Ltd. Started Nov 2012; status: completed.
02
Drugs
atesidorsen
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2012-003147-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003147-30.